These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21502953)

  • 1. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
    Rabiner EA; Beaver J; Makwana A; Searle G; Long C; Nathan PJ; Newbould RD; Howard J; Miller SR; Bush MA; Hill S; Reiley R; Passchier J; Gunn RN; Matthews PM; Bullmore ET
    Mol Psychiatry; 2011 Aug; 16(8):826-35, 785. PubMed ID: 21502953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.
    Ziauddeen H; Nestor LJ; Subramaniam N; Dodds C; Nathan PJ; Miller SR; Sarai BK; Maltby K; Fernando D; Warren L; Hosking LK; Waterworth D; Korzeniowska A; Win B; Richards DB; Vasist Johnson L; Fletcher PC; Bullmore ET
    Neuropsychopharmacology; 2016 Oct; 41(11):2647-57. PubMed ID: 27109624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
    Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G
    Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.
    Ignar DM; Goetz AS; Noble KN; Carballo LH; Stroup AE; Fisher JC; Boucheron JA; Brainard TA; Larkin AL; Epperly AH; Shearer TW; Sorensen SD; Speake JD; Hommel JD
    J Pharmacol Exp Ther; 2011 Oct; 339(1):24-34. PubMed ID: 21712426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating.
    Giuliano C; Robbins TW; Nathan PJ; Bullmore ET; Everitt BJ
    Neuropsychopharmacology; 2012 Nov; 37(12):2643-52. PubMed ID: 22805601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
    Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
    Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist.
    Nathan PJ; O'Neill BV; Bush MA; Koch A; Tao WX; Maltby K; Napolitano A; Brooke AC; Skeggs AL; Herman CS; Larkin AL; Ignar DM; Richards DB; Williams PM; Bullmore ET
    J Clin Pharmacol; 2012 Apr; 52(4):464-74. PubMed ID: 21610207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.
    Giuliano C; Goodlett CR; Economidou D; García-Pardo MP; Belin D; Robbins TW; Bullmore ET; Everitt BJ
    Neuropsychopharmacology; 2015 Dec; 40(13):2981-92. PubMed ID: 26044906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people.
    Cambridge VC; Ziauddeen H; Nathan PJ; Subramaniam N; Dodds C; Chamberlain SR; Koch A; Maltby K; Skeggs AL; Napolitano A; Farooqi IS; Bullmore ET; Fletcher PC
    Biol Psychiatry; 2013 May; 73(9):887-94. PubMed ID: 23245760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498.
    Nathan PJ; Bush MA; Tao WX; Koch A; Davies KM; Maltby K; O'Neill BV; Napolitano A; Skeggs AL; Brooke AC; Richards DB; Williams PM; Bullmore ET
    J Clin Pharmacol; 2012 Oct; 52(10):1456-67. PubMed ID: 22162534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism.
    Giuliano C; Robbins TW; Wille DR; Bullmore ET; Everitt BJ
    Psychopharmacology (Berl); 2013 May; 227(1):137-47. PubMed ID: 23299095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total-body imaging of mu-opioid receptors with [
    Hsieh CJ; Hou C; Lee H; Tomita C; Schmitz A; Plakas K; Dubroff JG; Mach RH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3273-3283. PubMed ID: 38722383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects.
    Ziauddeen H; Nathan PJ; Dodds C; Maltby K; Miller SR; Waterworth D; Song K; Warren L; Hosking L; Zucchetto M; Bush M; Johnson LV; Sarai B; Mogg K; Bradley BP; Richards DB; Fletcher PC; Bullmore ET
    J Clin Pharmacol; 2013 Oct; 53(10):1078-90. PubMed ID: 23934621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption.
    Nathan PJ; Bakker G
    Psychopharmacology (Berl); 2021 May; 238(5):1255-1263. PubMed ID: 31900526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.
    Ziauddeen H; Chamberlain SR; Nathan PJ; Koch A; Maltby K; Bush M; Tao WX; Napolitano A; Skeggs AL; Brooke AC; Cheke L; Clayton NS; Sadaf Farooqi I; O'Rahilly S; Waterworth D; Song K; Hosking L; Richards DB; Fletcher PC; Bullmore ET
    Mol Psychiatry; 2013 Dec; 18(12):1287-93. PubMed ID: 23147384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.
    Kohno M; Dennis LE; McCready H; Schwartz DL; Hoffman WF; Korthuis PT
    Drug Alcohol Depend; 2018 Nov; 192():186-192. PubMed ID: 30266003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity.
    Murray E; Brouwer S; McCutcheon R; Harmer CJ; Cowen PJ; McCabe C
    Psychopharmacology (Berl); 2014 Nov; 231(22):4323-35. PubMed ID: 24763910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.
    Chamberlain SR; Mogg K; Bradley BP; Koch A; Dodds CM; Tao WX; Maltby K; Sarai B; Napolitano A; Richards DB; Bullmore ET; Nathan PJ
    Psychopharmacology (Berl); 2012 Dec; 224(4):501-9. PubMed ID: 22752384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. μ-opioid receptor system mediates reward processing in humans.
    Nummenmaa L; Saanijoki T; Tuominen L; Hirvonen J; Tuulari JJ; Nuutila P; Kalliokoski K
    Nat Commun; 2018 Apr; 9(1):1500. PubMed ID: 29662095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid antagonism modulates wanting-related frontostriatal connectivity.
    Soutschek A; Weber SC; Kahnt T; Quednow BB; Tobler PN
    Elife; 2021 Nov; 10():. PubMed ID: 34761749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.